Literature DB >> 10545953

Perlecan is essential for cartilage and cephalic development.

E Arikawa-Hirasawa1, H Watanabe, H Takami, J R Hassell, Y Yamada.   

Abstract

Perlecan, a large, multi-domain, heparan sulfate proteoglycan originally identified in basement membrane, interacts with extracellular matrix proteins, growth factors and receptors, and influences cellular signalling. Perlecan is present in a variety of basement membranes and in other extracellular matrix structures. We have disrupted the gene encoding perlecan (Hspg2) in mice. Approximately 40% of Hspg2-/- mice died at embryonic day (E) 10.5 with defective cephalic development. The remaining Hspg2-/- mice died just after birth with skeletal dysplasia characterized by micromelia with broad and bowed long bones, narrow thorax and craniofacial abnormalities. Only 6% of Hspg2-/- mice developed both exencephaly and chondrodysplasia. Hspg2-/- cartilage showed severe disorganization of the columnar structures of chondrocytes and defective endochondral ossification. Hspg2-/- cartilage matrix contained reduced and disorganized collagen fibrils and glycosaminoglycans, suggesting that perlecan has an important role in matrix structure. In Hspg2-/- cartilage, proliferation of chondrocytes was reduced and the prehypertrophic zone was diminished. The abnormal phenotypes of the Hspg2-/- skeleton are similar to those of thanatophoric dysplasia (TD) type I, which is caused by activating mutations in FGFR3 (refs 7, 8, 9), and to those of Fgfr3 gain-of-function mice. Our findings suggest that these molecules affect similar signalling pathways.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10545953     DOI: 10.1038/15537

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  164 in total

Review 1.  Heparan sulfate: lessons from knockout mice.

Authors:  E Forsberg; L Kjellén
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 2.  A bit of give and take: the relationship between the extracellular matrix and the developing chondrocyte.

Authors:  Danielle J Behonick; Zena Werb
Journal:  Mech Dev       Date:  2003-11       Impact factor: 1.882

3.  Perlecan-stimulated nodules undergo chondrogenic maturation in response to rhBMP-2 treatment in vitro.

Authors:  Ronald R Gomes; Mary C Farach Carson; Daniel D Carson
Journal:  Connect Tissue Res       Date:  2003       Impact factor: 3.417

Review 4.  Genetic disorders of the skeleton: a developmental approach.

Authors:  Uwe Kornak; Stefan Mundlos
Journal:  Am J Hum Genet       Date:  2003-07-31       Impact factor: 11.025

Review 5.  Matrix remodeling during endochondral ossification.

Authors:  Nathalie Ortega; Danielle J Behonick; Zena Werb
Journal:  Trends Cell Biol       Date:  2004-02       Impact factor: 20.808

Review 6.  Extracellular matrix composition reveals complex and dynamic stromal-epithelial interactions in the mammary gland.

Authors:  Ori Maller; Holly Martinson; Pepper Schedin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-09-02       Impact factor: 2.673

7.  Heparan sulfate-dependent signaling of fibroblast growth factor 18 by chondrocyte-derived perlecan.

Authors:  Christine Y Chuang; Megan S Lord; James Melrose; Martin D Rees; Sarah M Knox; Craig Freeman; Renato V Iozzo; John M Whitelock
Journal:  Biochemistry       Date:  2010-07-06       Impact factor: 3.162

8.  A novel peptide sequence in perlecan domain IV supports cell adhesion, spreading and FAK activation.

Authors:  Mary C Farach-Carson; Anissa J Brown; Megan Lynam; Jeffrey B Safran; Daniel D Carson
Journal:  Matrix Biol       Date:  2007-10-10       Impact factor: 11.583

Review 9.  Role of perlecan in skeletal development and diseases.

Authors:  John Hassell; Yoshihiko Yamada; Eri Arikawa-Hirasawa
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

10.  Perlecan is required for FGF-2 signaling in the neural stem cell niche.

Authors:  Aurelien Kerever; Frederic Mercier; Risa Nonaka; Susana de Vega; Yuka Oda; Bernard Zalc; Yohei Okada; Nobutaka Hattori; Yoshihiko Yamada; Eri Arikawa-Hirasawa
Journal:  Stem Cell Res       Date:  2013-12-28       Impact factor: 2.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.